Open Access<p>Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy</p>
Author(s) -
Chad Moretz,
Beth Hahn,
John White,
Alyssa Goolsby Hunter,
Breanna Essoi,
Caitlin Elliott,
Riju Ray
Publication year - 2020
Publication title -
international journal of chronic obstructive pulmonary disease/international journal of copd
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 67
eISSN - 1178-2005
pISSN - 1176-9106
DOI - 10.2147/copd.s265037
Subject(s) - medicine , fluticasone propionate , salmeterol , copd , lama , obstructive lung disease , budesonide , physical therapy , corticosteroid
Long-acting muscarinic antagonist/long-acting β 2 -agonist (LAMA/LABA) provide greater improvements in lung function and symptoms than inhaled corticosteroid (ICS)/LABA in patients with chronic obstructive pulmonary disease (COPD). This study evaluated symptom burden and Global Initiative for Obstructive Lung Disease (GOLD) categorization among patients who recently initiated umeclidinium/vilanterol (UMEC/VI; LAMA/LABA) or fluticasone propionate/salmeterol (FP/SAL; ICS/LABA) single-inhaler dual therapy.